The clinical logic of this formula is a cascade: each active creates the conditions that allow the next to be fully effective.

Finasteride establishes the hormonal foundation. Pattern hair loss is a DHT-mediated disease. Treating it without suppressing DHT is treating symptoms against a persistent biological force actively driving follicular regression. Finasteride removes that force — reducing intrafollicular DHT by 60–70%, halting the miniaturization signal, and creating a hormonally favorable scalp environment in which follicular growth-stimulating therapy can work with rather than against the underlying biology.

Oral minoxidil builds on that foundation. With DHT suppression in place, minoxidil's growth-phase prolongation, perifollicular vasodilation, and VEGF-mediated angiogenesis act on follicles that are no longer being pushed toward regression — expressing their full growth-stimulating potential in a hormonal environment that supports rather than counteracts them. The two mechanisms are synergistic: finasteride creates the conditions; minoxidil capitalizes on them across every follicle simultaneously through systemic oral delivery.

Biotin ensures the output is structurally sound. The follicular biological activity that finasteride preserves and minoxidil enhances is only cosmetically meaningful if the hair shafts produced are thick, strong, and long enough to contribute to visible density. Biotin's support for keratin synthesis provides the structural raw material that makes follicular activity translate into visible, full-diameter, breakage-resistant hair.

Once-daily oral delivery serves adherence. Male pattern hair loss requires sustained, long-term, consistent pharmacological management — not a finite treatment course. The single once-daily tablet format of this formula reduces the regimen burden to its minimum, eliminating the separate topical application, separate oral dose, and separate supplement that multi-product protocols require. In a condition where missed doses and treatment fatigue are among the most common reasons for suboptimal outcomes, this simplicity is itself a meaningful clinical feature.

With consistent once-daily use as directed by your prescribing provider:

Halt or meaningful slowing of androgenetic hair loss progression through sustained DHT suppression

Preservation of existing hair density in follicles that remain active and responsive to treatment

Regrowth of hair in thinning areas — particularly the vertex scalp — in patients with early-to-moderate androgenetic alopecia

Prolonged anagen (growth) phase duration, allowing follicles to produce fuller, longer hair shafts before entering resting and shedding phases

Improved perifollicular microcirculation through VEGF-mediated angiogenesis and vasodilatory activity

Stronger, thicker, more elastically resilient hair shafts through biotin-supported keratin synthesis

Reduced hair breakage and improved hair shaft integrity

Visibly fuller, denser hair appearance as pharmacological growth activity is supported by structural shaft quality

Simplified, sustainable once-daily oral regimen supporting the long-term adherence that produces meaningful results

Results vary by individual, age, hair loss stage, and duration of therapy. Meaningful improvement in density and shedding reduction typically requires three to six months of consistent daily use. Maximum benefit is generally observed at twelve months and with continued treatment. Finasteride's protective effect reverses within weeks to months of discontinuation — ongoing therapy is the clinical expectation in androgenetic alopecia management. Earlier initiation relative to the onset of hair loss produces more favorable outcomes.

Take one tablet by mouth once daily, with or without food.

Food does not meaningfully affect the absorption of any of the three actives. Take Cedar at the same time each day to support consistent plasma levels and establish the daily habit that long-term adherence requires. Morning, midday, or evening — whichever fits most reliably into your routine.

If a dose is missed: Take as soon as remembered on the same day. If the missed dose is not recalled until the following day, skip it and resume your regular once-daily schedule. Do not take two tablets to compensate for a missed dose.

Duration: This is a long-term maintenance medication. Plan for a minimum six-month assessment period before evaluating response. Continue therapy indefinitely as long as it is well tolerated and clinically appropriate, in consultation with your provider.

This is a prescription-only compounded medication for use in men. It contains finasteride, a teratogenic 5-alpha reductase inhibitor, and oral minoxidil, a systemic vasodilator. Full patient counseling is required before initiating therapy.

Contraindications:

Women — especially pregnant women or women who may become pregnant: Finasteride is teratogenic to male fetuses — exposure during pregnancy is associated with abnormalities of the external genitalia. Women who are pregnant or may become pregnant must not take this product and must not handle crushed or broken tablets, as finasteride can be absorbed through skin contact. This product must be stored away from women of childbearing potential and kept out of reach of children at all times.

Patients under 18: Not studied or indicated in pediatric patients.

Known hypersensitivity: Patients with documented allergy to finasteride, minoxidil, or biotin should not use this product.

Significant cardiovascular disease: Oral minoxidil retains systemic vasodilatory activity even at low hair loss doses. Patients with significant cardiovascular conditions — including heart failure, recent myocardial infarction, coronary artery disease, significant arrhythmia, or uncontrolled hypertension — require individualized cardiovascular evaluation before initiating oral minoxidil. Discuss your full cardiac history with your prescribing provider.

Potential Side Effects:

Finasteride-related:

Decreased libido, erectile dysfunction, or reduced ejaculate volume — reported in a minority of patients (approximately 1–4% in clinical trials); reversible upon discontinuation in the majority of cases; discuss with your provider if experienced

Breast tenderness or gynecomastia — uncommon; report to your provider

Mood changes — rare; reported in post-marketing surveillance; report significant mood changes promptly

Oral minoxidil-related:

Hypertrichosis (increased fine body hair) — the most commonly reported side effect at low oral doses; typically involves fine facial, arm, or torso hair; usually cosmetically manageable; discuss with your provider if bothersome

Fluid retention or ankle edema — uncommon at low doses; more likely in patients with cardiovascular or renal conditions; report promptly

Mild tachycardia or palpitations — uncommon; report promptly, particularly in patients with cardiovascular history

Transient increased shedding during the first four to eight weeks — follicles being pushed from resting to active phase; expected and temporary; contact your provider before discontinuing if this occurs

Biotin-related:

Exceptionally well tolerated; adverse reactions at supplemental doses are rare

Laboratory test interference — see Drug Interactions below

Antihypertensive medications: Oral minoxidil has vasodilatory activity — additive blood pressure lowering may occur with concurrent antihypertensives. Inform your provider of all blood pressure medications before initiating this formula.

Other vasodilators or cardiovascular medications: Discuss all cardiovascular medications with your provider before initiating therapy.

Oral dutasteride: Patients on systemic dutasteride for any indication should inform their provider — concurrent dual 5-alpha reductase inhibition should be clinically managed rather than inadvertently combined.

Biotin-based laboratory immunoassays — critical interaction: Biotin supplementation at therapeutic doses interferes with biotin-streptavidin immunoassay platforms, which are used in many standard laboratory tests including thyroid function panels (TSH, free T4, free T3), cardiac troponin assays, fertility hormone panels (LH, FSH, testosterone), and vitamin D assays. Interference can produce falsely elevated or falsely low results — potentially leading to misdiagnosis or inappropriate treatment changes. Always inform all providers and laboratory staff that you are taking biotin before any blood testing. Some providers recommend discontinuing biotin 48–72 hours before planned laboratory testing; discuss the appropriate approach with your supervising provider.

CYP3A4 inducers: Finasteride is hepatically metabolized; significant CYP3A4 inducers such as rifampin or certain anticonvulsants may reduce finasteride plasma concentrations. Discuss all medications with your provider.

Store at room temperature, 68°F – 77°F (20°C – 25°C), away from direct heat, humidity, and light

Keep container tightly closed

Do not freeze

Keep strictly out of reach of women of childbearing potential and children — finasteride must not be handled by pregnant women or women who may become pregnant

Do not use beyond the labeled expiration date